CGRP Antibodies as Prophylaxis in Migraine
(2018) In Cell 175(7). p.1719-1719- Abstract
Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF. Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system.... (More)
Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF. Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.
(Less)
- author
- Edvinsson, Lars LU
- publishing date
- 2018
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cell
- volume
- 175
- issue
- 7
- pages
- 1 pages
- publisher
- Cell Press
- external identifiers
-
- scopus:85058023044
- ISSN
- 0092-8674
- DOI
- 10.1016/j.cell.2018.11.049
- language
- English
- LU publication?
- no
- id
- a749175e-a6b7-43e7-b2b4-99f6780916e2
- date added to LUP
- 2018-12-18 13:10:31
- date last changed
- 2022-04-25 19:56:26
@misc{a749175e-a6b7-43e7-b2b4-99f6780916e2, abstract = {{<p>Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF. Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.</p>}}, author = {{Edvinsson, Lars}}, issn = {{0092-8674}}, language = {{eng}}, number = {{7}}, pages = {{1719--1719}}, publisher = {{Cell Press}}, series = {{Cell}}, title = {{CGRP Antibodies as Prophylaxis in Migraine}}, url = {{http://dx.doi.org/10.1016/j.cell.2018.11.049}}, doi = {{10.1016/j.cell.2018.11.049}}, volume = {{175}}, year = {{2018}}, }